Gilead Sciences Inc. and Goldfinch Bio Inc. announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.

Boston-based Alexion’s Ultomiris (ravulizumab-cwvz) hit the primary objective in a Phase III study of complement inhibitor-naïve patients with atypical hemolytic uremic syndrome.

Tokyo’s Otsuka Pharmaceutical is acquiring Waltham, Mass.-based Visterra for $430 million in cash. The deal is expected to close during third-quarter 2018.

As Rigel Pharmaceuticals awaits a regulatory decision for Tavalisse (fostamatinib) for a platelet disorder, the company reported a developmental setback for the therapy in another clinical trial.

Eli Lilly and Co’s Jardiance diabetes drug slashed the risk of progressive kidney disease in adults with type 2 diabetes in a large trial.

People taking common heartburn medications known as proton pump inhibitors (PPIs) are at increased risk of new and severe kidney disease, according to a U.S. study. Among hundreds of thousands of patients in Department of Veterans Affairs (VA) databases, new users of PPIs without kidney disease were 30 percent more likely to develop chronic kidney […]

Kidney dialysis provider Fresenius Medical Care (FMC) expects more than 70 percent of eligible U.S. patients to have switched to cheaper alternative anemia treatment Mircera by the end of March, the German group’s chief executive said. About 155,000 of FMC’s 185,000 U.S. dialysis patients require treatment against anemia, or deficiency of red blood cells. The […]

Atara Biotherapeutics Inc said it would stop developing its kidney drug after the treatment failed to meet the main goal of a mid-stage study. The drug developer said on Monday that the drug, PINTA 745, did not improve physical function, levels of inflammation and blood sugar in patients in the study. Atara’s shares fell nearly […]

LONDON – Looking to strengthen its cardiovascular and metabolic offerings, London-based AstraZeneca (AZN) is snapping up Bay Area-based ZS Pharma (ZSPH) in a deal worth $2.7 billion in hopes of leveraging that company’s ion-trap technology treatments for hyperkalemia into a blockbuster drug. The deal, which will see AstraZeneca spend $90 per share for ZS Pharma, […]

Bayer will move a new heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular medicine, after the experimental medicine proved better than an older rival in a mid-stage trial. Having done well with recently launched drugs like stroke prevention pill Xarelto and eye treatment Eylea, the German group is eager to […]